Table 1.
Impact of candidate genes on tumorigenesis in vivo
| RCASBP– | Age (wk) | Tumor burden (mm3) | Lymph node metastasis (%) | Liver metastasis (%) |
| ALPP | 12 | 8.1 ± 4.5 | 0/5 mice (0) | 0/5 mice (0) |
| ALPP | 16 | 99.7 ± 19.4 | 0/10 mice (0) | 0/10 mice (0) |
| RHAMMB | 12 | 16.2 ± 8.9 | 0/6 mice (0) | 0/6 mice (0) |
| RHAMMB | 16 | 298.3 ± 121.3 | 8/11 mice (73) | 8/12 mice (67) |
| Bcl-xL | 16 | 150.5 ± 23 | 7/15 mice (46) | 0/6 mice (0) |
| FLAG-PEG10 | 16 | 57.8 ± 26.8 | 2/8 mice (25) | 0/8 mice (0) |
| FLAG-FLJ10540 | 16 | 126.1 ± 54.3 | 4/7 mice (57) | 2/7 mice (28) |
| FLAG-FLJ11252 | 16 | 41.2 ± 30.9 | 0/7 mice (0) | 0/7 mice (0) |
| FLJ11164 | 16 | 43.8 ± 25.1 | 1/9 mice (11) | 0/6 mice (0)* |
RCASBP retroviruses carrying indicated cDNAs were introduced to RIP-Tag; RIP-tva mice through intracardiac injection at 7 wk of age. Mice were euthanized at 12 or 16 wk of age for measurement of tumor burden and for metastasis survey. A standard formula for tumor volume was applied (volume [mm3] = 0.52 × width2 × length). Tumor burden is the sum of the tumor volume per mouse.
*Mice having micrometastases with fewer than five cells were excluded.